Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Twitter Feed
-
An editorial published in the Lancet Neurology suggests that patient engagement is key to improving epilepsy outcomes. Read the full article here: https://t.co/3RDYCYgSae https://t.co/0xXGxahpiQ
— UCB News (@ucb_news) 25.03.2019 -
Are you looking for an IT career path with rotation and training opportunities? See what Norbert shares about his experience at UCB and apply at https://t.co/nTUueuplnF https://t.co/k3Wybd4GIH
— UCB News (@ucb_news) 18.03.2019 -
The need for #patients to be fully aware of the #sideeffects of their treatment was rated as very high by patient groups across all therapy areas. ➡️ Want to find out more results of our global survey? ✅ Click here: https://t.co/sw9X1zRNAc https://t.
— UCB News (@ucb_news) 15.03.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
